MINERALYS THERAPEUTICS, INC. Payments of Stock Issuance Costs
MINERALYS THERAPEUTICS, INC. (MLYS) reported Payments of Stock Issuance Costs of $16.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsOfStockIssuanceCosts · last filed 2026-08-11
- MINERALYS THERAPEUTICS, INC. payments of stock issuance costs for the quarter ending 2026-06-30 was $15.00K, a 68.09% decline year-over-year.
- MINERALYS THERAPEUTICS, INC. payments of stock issuance costs for the quarter ending 2026-03-31 was $1.00K, a 90.00% decline year-over-year.
- MINERALYS THERAPEUTICS, INC. payments of stock issuance costs for the quarter ending 2025-12-31 was $305.00K, a 548.94% increase year-over-year.
- MINERALYS THERAPEUTICS, INC. payments of stock issuance costs for the quarter ending 2025-09-30 was $29.00K, a 29.27% decline year-over-year.
- MINERALYS THERAPEUTICS, INC. payments of stock issuance costs for fiscal 2025 was $391.00K, a 10.11% decline from fiscal 2024.
- MINERALYS THERAPEUTICS, INC. payments of stock issuance costs for fiscal 2024 was $435.00K.
- MINERALYS THERAPEUTICS, INC. payments of stock issuance costs for fiscal 2023 was $0.00.
| Period end | Payments of Stock Issuance Costs 3 month | Payments of Stock Issuance Costs 6 month | Payments of Stock Issuance Costs 9 month | Payments of Stock Issuance Costs 12 month |
|---|---|---|---|---|
| 2026-06-30 | $15.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $16.00K 10-Q · filed 2026-08-11 | $321.00K derived: sum of 3 quarters · filed 2026-08-11 | $350.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $1.00K 10-Q · filed 2026-05-06 | $306.00K derived: sum of 2 quarters · filed 2026-05-06 | $335.00K derived: sum of 3 quarters · filed 2026-05-06 | $382.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $305.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $334.00K derived: sum of 2 quarters · filed 2026-03-12 | $381.00K derived: sum of 3 quarters · filed 2026-08-11 | $391.00K 10-K · filed 2026-03-12 |
| 2025-09-30 | $29.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $76.00K derived: sum of 2 quarters · filed 2026-08-11 | $86.00K 10-Q · filed 2025-11-10 | $133.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $47.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $57.00K 10-Q · filed 2026-08-11 | $104.00K derived: sum of 3 quarters · filed 2026-08-11 | $145.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $10.00K 10-Q · filed 2026-05-06 | $57.00K derived: sum of 2 quarters · filed 2026-05-06 | $98.00K derived: sum of 3 quarters · filed 2026-05-06 | $382.00K derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $47.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $88.00K derived: sum of 2 quarters · filed 2026-03-12 | $372.00K derived: sum of 3 quarters · filed 2026-03-12 | $435.00K 10-K · filed 2026-03-12 |
| 2024-09-30 | $41.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $325.00K derived: sum of 2 quarters · filed 2025-11-10 | $388.00K 10-Q · filed 2025-11-10 | $388.00K derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | $284.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $347.00K 10-Q · filed 2025-08-12 | $347.00K derived: sum of 3 quarters · filed 2025-08-12 | $347.00K derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $63.00K 10-Q · filed 2025-05-12 | $63.00K derived: sum of 2 quarters · filed 2025-05-12 | $63.00K derived: sum of 3 quarters · filed 2025-05-12 | $63.00K derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-12 | $0.00 derived: sum of 2 quarters · filed 2025-02-12 | $0.00 derived: sum of 3 quarters · filed 2025-02-12 | $0.00 10-K · filed 2025-02-12 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $0.00 derived: sum of 2 quarters · filed 2024-11-12 | $0.00 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $0.00 10-Q · filed 2024-08-13 | ||
| 2023-03-31 | $0.00 10-Q · filed 2024-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |